Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Wockhardt’s SEC nod for Zaynich marks a major step toward India’s first home-grown, dual‑mechanism anti‑Gram‑negative launched in the carbapenem‑resistan...
